Galmed Pharmaceuticals Ltd. (GLMD) Analysis

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 353% surge in interest Protagenic Therapeutics (PTIX), 345% surge in interest Hepion Pharmaceuticals (HEPA), 310% surge in interest Rigel Pharmaceuticals (RIGL), 290% surge in interest Bolt Biotherapeutics (BOLT), 274% surge in interest Palatin Technologies (PTN), 274% surge in interest Krystal Biotech (KRYS), 240% surge in

If you saw my other post on $GLMD, you will see why I’m beyond bullish here. The daily chart is setting up beautifully as we get closer to some upcoming catalyst. We were told in April that we would get more info within 90 days on their licensing agreement for the development and commercialization of a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation that allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, Liraglutide etc.). Most don’t unders...

On April 28, Galmed Pharmaceuticals **($GLMD)**, a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced that it has signed a binding term-sheet with Entomus s.r.o. for a license agreement for the development and commercialization of a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation that allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, Liraglutide etc.). What separates their GLP-1 ...

$GLMD is a clinical-stage biopharmaceutical company focused on developing treatments for liver, metabolic, and fibrotic diseases. Galmed Pharmaceuticals recently announced a **major scientific and strategic milestone**: the discovery of a proprietary pharmacodynamic (PD) blood-based biomarker signature for its lead candidate, Aramchol — the industry's most clinically advanced stearoyl-CoA desaturase 1 (SCD1) inhibitor. This newly characterized biomarker profile, derived from plasma samples in th...

Not financial advice just wanted to share a setup I’ve been watching closely that I feel is flying way under the radar. $GLMD is currently trading around $1.60–$1.80 with: • Book value estimated between $8–$12 • No debt and strong cash position • Low float (under 10M adjusted) • No outstanding toxic warrants • A potential GLP-1 / NASH catalyst expected in the next few weeks This reminds me of a few past setups that ended up rerating quickly once volume came in or a press release dropped. It’s ...

$UMAC it’s already up 100%. Now I’m watching $GLMD closely, catalysts and powerful news that can send this soaring many dollars to the upside are approaching (90 days, from 4-28-25 is the max) ! This low-float biotech just signed a binding term sheet with Entomus to enter the $120B GLP-1 space through a sublingual semaglutide formulation. With global GLP-1 patent expirations starting in 2026 and a 505(b)(2) regulatory pathway in play, the timing is much closer than most realize. Meanwhile, $GLMD...